Clinical trials: Zoledronic acid
Prostate Adenocarcinoma
ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma
This study will determine the delayed neurotoxicity (12 months) of a hypofractionated high dose irradiation (3 Gy x 9) associated with zoledronic acid.
- Trial name
- GEMO (NCT01219790)
- Testing
- external radiotherapy, Acide zoledronic
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Institut Cancerologie de l'Ouest
Multiple Myeloma
THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
The marked activity of thalidomide (thal) and dexamethasone (dex) in relapsed and refractory multiple myeloma (MM) provided the basis for this phase 2 clinical study aimed at investigating the efficacy and toxicity of thal-dex…
- Trial name
- NCT01341262
- Testing
- Thalidomide, Dexamethasone, Zoledronic acid
- Volunteers
- 378 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Osteonecrosis
Osteonecrosis of the Hip and Bisphosphonate Treatment
Osteonecrosis of the hip is an important cause of musculoskeletal disability and finding therapeutic solutions has proven to be challenging.
- Trial name
- BONES (NCT00781261)
- Testing
- Zoledronic Acid
- Where
- 5 sites in Australia
- Volunteers
- 120 people
- Sponsor
- University of Sydney
Osteoporosis
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.
- Trial name
- NCT00097812
- Testing
- zoledronic acid
- Where
- 13 sites in United States, Germany
- Volunteers
- 220 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
This study aims to determine whether early treatment with zoledronic acid, that is given during the early phase of advanced prostate cancer, will be more efficacious than delayed treatment
- Trial name
- NCT00242567
- Testing
- Zoledronic Acid, Androgen Deprivation Therapy (ADT)
- Where
- 27 sites in Australia, Brazil and 8 more
- Volunteers
- 522 people
- Sponsor
- Novartis Pharmaceuticals
Nasopharyngeal Cancer
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
The purpose of this study is to assess the efficacy of addition of zometa to anti-neoplastic treatment compared with anti-neoplastic treatment alone, as measured by the primary efficacy variable of SREs (Skeletal Related Events)…
- Trial name
- NCT00697619
- Testing
- Zometa (zoledronic acid)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Bone Loss, Prostate Cancer
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
The primary objective of this study is to determine whether zoledronic acid (Zometa) given once annually increases bone mineral density in men receiving hormone therapy for prostate cancer.
- Trial name
- NCT00181584
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Osteoporosis
Denosumab Sequential Therapy
Denosumab is a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis. Although denosumab has excellent effect to increase bone mass and prevent fracture in FREEDOM study with very low complications…
- Trial name
- DST (NCT03868033)
- Testing
- Zoledronic Acid, Denosumab
- Where
- Taiwan
- Volunteers
- 101 people
- Sponsor
- National Taiwan University Hospital
Idiopathic Inflammatory Myopathies, Osteoporosis, Osteopenia
Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
Idiopathic inflammatory myopathies (IIM) patients are at high risk of development of reduced bone mineral density due to impairment of functional status due to the disease and a relatively high dose of glucocorticoid use for the…
- Trial name
- NCT04034199
- Testing
- Denosumab, Zoledronic Acid
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Kwong Wah Hospital
Risk Factors for or a Diagnosis of Osteoporosis
Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone
The purpose of this study is to determine the maximum tolerated concentration (MTC) of bisphosphonate with a fixed dose of rHuPH20 administered SC, the MTC of bisphosphonate without rHuPH20 administered SC, the optimal dose of…
- Trial name
- NCT00807963
- Testing
- rHuPH20, zoledronic acid
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Halozyme Therapeutics
Low Bone Mineral Density, Postmenopausal Osteoporosis
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low…
- Trial name
- NCT00896532
- Testing
- Alendronate, Teriparatide, Romosozumab
- Volunteers
- 419 people
- Sponsor
- Amgen
Crohn's Disease, Osteopenia
Zoledronate for Osteopenia in Pediatric Crohn's
Background: Up to 30% of children and adolescents with Crohn's disease have decreased bone strength, or decrease bone density, called osteopenia.
- Conditions
- Crohn's Disease, Osteopenia, Osteoporosis
- Trial name
- NCT00798473
- Testing
- zoledronic acid, IV saline infusion
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Breast Cancer, Prostate Cancer
Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
This is an open-label exploratory study of CTAP101 Capsules in patients with bone metastases arising from either breast or prostate cancer, who are taking anti-resorptive therapy.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms, Hypocalcemia
- Trial name
- NCT02274623
- Testing
- CTAP101 Capsules
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- OPKO Health, Inc.
Prostate Cancer
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
The primary goal for this trial is to assess the change in PET scans with the administration of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer.
- Trial name
- NCT01205646
- Testing
- zoledronate therapy, PET Scan
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Osteoporosis, Prostate Cancer
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
RATIONALE: Zoledronate may prevent bone loss associated with long term androgen deprivation therapy. It is not yet known whether zoledronate combined with calcium is more effective than calcium alone in preventing bone loss.
- Trial name
- NCT00058188
- Testing
- cholecalciferol, calcium gluconate, zoledronic acid
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Northwestern University
Trochanteric Fracture of Femur, Osteoporotic Fracture of Femur
FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA
The goal of this clinical trial is to investigate the new bone formation around a metal device in the femoral head in patients with osteoporotic hip fractures undergoing surgical treatment with nails.
- Conditions
- Trochanteric Fracture of Femur, Osteoporotic Fracture of Femur, Hip Fractures, Bone Density, Low
- Trial name
- NCT06135298
- Testing
- OSTEOSYNTHESIS, Zoledronic acid, CERAMENT BONE VOID FILLER (BVF)
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Aksaray University
Breast Neoplasms
Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
This study will evaluate the safety/efficacy of zoledronic acid when given by intravenous infusion every 4 weeks in addition to letrozole as endocrine therapy in postmenopausal patients with hormone responsive breast cancer
- Trial name
- FEMZONE (NCT00375752)
- Testing
- Letrozole, Zolendronic Acid
- Where
- 27 sites in Germany
- Volunteers
- 168 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
Sorafenib ,an oral multikinase inhibitor targeting several tyrosine-kinase receptors with antiangiogenesis and antiproliferation of HCC, is the first approved target therapy for HCC.
- Trial name
- NCT01259193
- Testing
- Sorafenib and Zoledronic Acid
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Osteosarcoma
Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma
This trial will be a pilot study to find out if zoledronic acid improves the response to chemotherapy in high grade osteosarcoma. In arm A of the study, 40 adult patients will be randomised into two groups.
- Trial name
- ZOL (NCT00691236)
- Testing
- Zoledronic acid, Standard chemotherapy
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Hospital
Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer
- Trial name
- ZAMBONI (NCT07043608)
- Testing
- Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kelly Fitzgerald, MD